Gilead breaks ground on Foster City biologics facility in $32 billion US investment pushPUBT·4 hours agoGILD+0.52%GIS
Gilead Sciences director Anthony Welters disposes of USD 2.64 million in common sharesPUBT·8 hours agoGILD+0.52%GIS
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsCNBC·8 hours agoGILD+0.52%GIS
Abbott Laboratories Stock Underperforms Thursday When Compared To CompetitorsMarketWatch Automated·10 hours agoABT-2.20%
AbbVie Inc. Stock Underperforms Thursday When Compared To CompetitorsMarketWatch Automated·10 hours agoABBV-1.81%
Corcept Endocrinology President Sean Maduck disposes of 30,955 Corcept shares worth $3.88 millionPUBT·10 hours agoCORT-2.40%
10 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·13 hours agoCNC-0.21%AMGN-0.76%
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?Unusual Whales·15 hours agoAZN-1.05%AMGN-0.76%
HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionPUBT·16 hours agoAMGN-0.76%02142-7.36%
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens | GILD Stock NewsStockTitan·17 hours agoGILD+0.52%GIS
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of strokePress Releases·17 hours agoABT-2.20%
Cancer Drug Sales Power Up Kelun-Biotech’s Profit Enginebenzinga_article·19 hours ago06990-2.86%MRK-2.33%
AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial SuccessTip Ranks·20 hours agoAZN-1.05%AMGN-0.76%
Parallax Volatility Advisers L.P. Trims Holdings in Gilead Sciences, Inc. $GILDMarket Beat·20 hours agoGILD+0.52%GIS
